IndEx-2: Assessing the impact of antigen density on the efficacy and safety of immunotherapies

Welcome back to our scientific resources section of our blog, where we focus on cutting-edge discoveries. Today, we are thrilled to share with you a presentation delivered by none other than our Chief Scientific Officer, Dr Agapitos Patakas, at the prestigious PEGS Boston 2023 conference.

The number of antibody-targeted immuno-oncology therapeutics in development is growing year on year, yet there persists a lack of in vitro systems to interrogate the efficacy and safety of these modalities. In the following presentation, Dr Patakas will describe our IndEx-2 system, an in vitro cell-based platform which allows the expression of one, or two, target antigens over a range of biologically relevant levels. This system allows the determination of the precise antigen density activation thresholds of targeted candidate immunotherapies, enabling selection of candidates with improved efficacy and enhanced safety profiles at the discovery stage.

Without further ado, let’s delve into the realm of IndEx-2 and its implications for immune-directed therapies, as presented by Dr Agapitos Patakas; watch our video.

Stay tuned for more video content and other scientific resources on our blog.